Orthopediatrics (KIDS) Stock
Specialized orthopedic implants and instruments maker for children. Here's the price, business snapshot, and what's worth knowing about Orthopediatrics in August 2026.
Orthopediatrics Corp (KIDS) designs, develops and sells paediatric orthopaedic implants, instruments and biologics tailored to children. The company focuses on smaller anatomies and specialised needs — plates, screws, spinal systems and growth modulation products — and supplies hospitals, surgeons and distributors across multiple markets. Revenue growth is typically driven by new product introductions, increasing surgeon adoption and selective acquisitions, while margins reflect manufacturing, R&D and distribution costs. With a market capitalisation around $449 million, KIDS is a small-cap medical devices company and can be more volatile than larger peers. Key factors to watch include product approvals, clinical outcomes, reimbursement trends, and the effectiveness of commercial roll-outs. Cash position and debt levels will influence its runway for innovation and expansion. This information is general and educational only, not personal advice; investors should assess suitability, perform their own research and be aware that values can fall as well as rise.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Orthopediatrics Corp. stock with a target price of $30.55, indicating strong potential growth.
Financial Health
Orthopediatrics is showing strong revenue and profit margins, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Child-focused devices
Specialist products address paediatric needs and can command niche demand, though market uptake varies by surgeon familiarity and evidence.
Innovative pipeline
New product introductions and clinical data may drive adoption, but development and regulatory hurdles can delay commercial benefits.
Global expansion potential
International distribution offers growth opportunities, balanced by reimbursement differences and the costs of scaling operations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
